Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà, +127

The Lancet Oncology

Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor +6

Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells

Takashi Inozume, Ken‐ichi Hanada, Qiong J. Wang, +4

Journal of Immunotherapy

ImmunologyImmune RegulationImmunoeditingImmunologic MechanismImmunotherapeutics +19

Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase

Takashi Inozume, Tomonori Yaguchi, Junpei Furuta, +3

Journal of Investigative Dermatology

Cancer ImmunosurveillanceEffector PhaseMelanomaImmunologyImmune Checkpoint Inhibitor +4

Immune evasion through mitochondrial transfer in the tumour microenvironment

Hideki Ikeda, Katsushige Kawase, Tatsuya Nishi, +32

Nature

PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes

Joji Nagasaki, Takashi Inozume, Nicolas Sax, +23

Cell Reports

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

Naoya Yamazaki, Tatsuya Takenouchi, Manabu Fujimoto, +11

Cancer Chemotherapy and Pharmacology

Phase 1BAnti-pd-1 Monoclonal AntibodyMedicineMelanomaImmunology +5

TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment

Shusuke Kawashima, Takashi Inozume, Masahito Kawazu, +18

Journal for ImmunoTherapy of Cancer

A Case of Metastatic Extramammary Paget’s Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy

Fumie Hanawa, Takashi Inozume, Kazutoshi Harada, +3

Case Reports in Dermatology

Tumor BiologyAdvanced Extramammary PagetSurgical OncologyPaclitaxel Combination TherapyBreast Oncology +12

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Andrew Bottomley, Corneel Coens, Justyna Mierzynska, +129

The Lancet Oncology

Health-related Quality-of-life ResultsSurgical OncologyOncologyMelanomaImmunology +7

Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses

Tomonori Yaguchi, Asuka Kobayashi, Takashi Inozume, +9

Cellular and Molecular Immunology

InflammationAllergyAutoimmune DiseaseHuman Immune ResponsesMedicine +7